News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

May 16, 2018
Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, which is...

More
May 10, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2018. Cash and investments in marketable securities at March 31, 2018 were $333.8...

More
May 8, 2018

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in-class...

More
May 3, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 10, 2018, after the close of U.S.-based financial markets. Howard Robin, president and...

More
Apr 30, 2018

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host an analyst and investor event with clinical investigators on Saturday, June 2, 2018 at 6:45 p.m. CDT in Chicago, IL during the...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide